{
  "id": 7372409,
  "title": "Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M Milestone",
  "url": "https://urgent.news/2026/09/13/novartis-nvs-just-handed-monte-rosa-glue-a-50m-milestone",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-13T09:29:12.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/novartis-nvs-just-handed-monte-092912734.html"
  },
  "original_language": "en",
  "account": "On September 8, Swiss pharmaceutical company Monte Rosa Therapeutics announced that Novartis, its partner in developing a drug targeting the VAV1 protein, had begun enrolling patients in a Phase 2 trial of their investigational drug MRT-6160. If the trial is successful, Monte Rosa will receive a $50 million payment from Novartis, marking the first milestone in a potential deal worth up to $2.1 billion. Monte Rosa is still several years away from generating revenue from any of its products, so this payment significantly improves its financial outlook. The company is currently running a Phase 2 trial of MRT-6160 in patients with Sjögren's syndrome, a disease that affects the salivary and tear glands and for which there are currently few treatment options. Novartis is funding the entire Phase 2 trial, which will track participants for up to a year to determine the optimal dose before moving on to a Phase 3 program. Monte Rosa will also receive additional payments if the drug progresses to Phase 2 studies for other immune conditions. Sjögren's syndrome is a relatively common disease, affecting about 0.25% of the population, and is often underdiagnosed. Monte Rosa's VAV1-targeted drug has already shown promising results in earlier trials, reducing VAV1 protein levels by over 90% in patients' T cells and reducing inflammation without causing serious side effects. Monte Rosa also has two other programs in development: MRT-8102, which is being tested in patients with elevated cardiovascular risk, and MRT-2359, which is being tested in combination with apalutamide in patients with prostate cancer. Monte Rosa has $626 million in cash and equivalents, which should be sufficient to fund the company's operations through 2029. However, Monte Rosa's financial situation has been strained in recent quarters, with revenue dropping from $23.2 million to $9.0 million and research spending rising from $30.7 million to $48.0 million. The company's net loss expanded to $43.4 million in the second quarter of 2026, more than triple the $12.3 million loss from the same period in 2025. Despite these challenges, Monte Rosa continues to make progress in its drug development efforts, and positive results from its upcoming trials could provide the company with the runway it needs to reach later-stage, more definitive results.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}